Katherine R Tuttle Selected Research

Protein Kinase C beta

11/2008	Protein kinase C-beta inhibition for diabetic kidney disease.
9/2007	Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
7/2007	Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
11/2005	The effect of ruboxistaurin on nephropathy in type 2 diabetes.
4/2005	The next generation of diabetic nephropathy therapies: an update.
3/2005	Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C.
9/2003	A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katherine R Tuttle Research Topics

Disease

40	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 07/2003
31	Chronic Renal Insufficiency 01/2022 - 11/2006
30	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2005
23	Albuminuria 01/2021 - 01/2005
18	Kidney Diseases (Kidney Disease) 10/2021 - 01/2005
16	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 06/2003
11	Hypertension (High Blood Pressure) 01/2021 - 06/2003
10	Inflammation (Inflammations) 01/2022 - 04/2005
9	Chronic Kidney Failure (Chronic Renal Failure) 12/2022 - 01/2012
9	Renal Insufficiency (Renal Failure) 01/2022 - 01/2005
7	Fibrosis (Cirrhosis) 01/2021 - 03/2005
6	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2003
6	Renal Artery Obstruction (Renal Artery Stenosis) 01/2019 - 01/2014
5	Obesity 01/2021 - 12/2005
5	Heart Failure 01/2021 - 01/2014
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 01/2002
5	Myocardial Infarction 11/2016 - 01/2005
4	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 10/2014
4	Dyslipidemias (Dyslipidemia) 01/2021 - 03/2010
4	Proteinuria 01/2021 - 03/2015
3	Disease Progression 01/2022 - 04/2020
3	Infections 01/2021 - 12/2017
3	Body Weight (Weight, Body) 01/2021 - 09/2011
3	Diabetes Mellitus 01/2018 - 09/2007
3	Stroke (Strokes) 11/2016 - 01/2005
3	Isolated Systolic Hypertension 01/2016 - 03/2006
3	Hyperuricemia 03/2006 - 06/2003
2	Ketosis 01/2021 - 01/2021
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2021 - 08/2020
2	Anemia 11/2018 - 03/2010
2	Insulin Resistance 09/2008 - 12/2005
2	Hyperinsulinism (Hyperinsulinemia) 03/2006 - 12/2005
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2006 - 12/2005
2	Atherosclerosis 01/2005 - 11/2004
1	COVID-19 01/2022
1	Edema (Dropsy) 01/2022
1	Hyperglycemia 01/2022
1	Hyperkalemia 01/2022

Drug/Important Bio-Agent (IBA)

18	CreatinineIBA 01/2021 - 11/2005
10	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 03/2006
9	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2018
9	AlbuminsIBA 01/2018 - 11/2005
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2012
7	Uric Acid (Urate)IBA 01/2020 - 06/2003
7	ruboxistaurinIBA 04/2015 - 04/2005
7	Protein Kinase C betaIBA 11/2008 - 09/2003
6	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2019
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2021 - 09/2007
6	Antihypertensive Agents (Antihypertensives)IBA 01/2019 - 11/2007
5	Insulin Glargine (Lantus)FDA Link 01/2022 - 05/2014
5	Serum Amyloid A Protein (Serum Amyloid A)IBA 01/2019 - 03/2015
5	Proteins (Proteins, Gene)FDA Link 01/2016 - 03/2005
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 12/2018
4	Insulin (Novolin)FDA Link 01/2022 - 03/2006
4	dulaglutideIBA 01/2021 - 01/2017
4	Angiotensin Receptor AntagonistsIBA 01/2018 - 09/2007
4	CholesterolIBA 01/2016 - 01/2005
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 01/2017
3	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022 - 10/2014
3	IncretinsIBA 01/2021 - 01/2019
3	Hypoglycemic Agents (Hypoglycemics)IBA 10/2020 - 08/2017
3	Allopurinol (Remid)FDA LinkGeneric 01/2020 - 03/2006
3	Cystatin CIBA 01/2019 - 01/2016
3	Advanced Glycation End ProductsIBA 03/2014 - 11/2010
3	Amino Acids FDA Link 07/2013 - 01/2002
2	SodiumIBA 01/2022 - 01/2018
2	Serum AlbuminIBA 10/2020 - 08/2020
2	Janus KinasesIBA 11/2018 - 03/2014
2	Pharmaceutical PreparationsIBA 01/2018 - 08/2010
2	MineralsIBA 01/2018 - 03/2010
2	HDL CholesterolIBA 01/2018 - 01/2016
2	Messenger RNA (mRNA)IBA 03/2015 - 03/2005
2	ReninIBA 07/2014 - 01/2009
2	Exenatide (Byetta)FDA Link 05/2014 - 08/2013
2	Transforming Growth Factor beta (TGF-beta)IBA 09/2007 - 04/2007
2	FructoseIBA 03/2006 - 12/2005
1	empagliflozinIBA 01/2022
1	insulin degludecIBA 01/2022
1	Mineralocorticoid Receptor AntagonistsIBA 01/2022
1	Blood Glucose (Blood Sugar)IBA 01/2022
1	Mitochondrial DNA (mtDNA)IBA 01/2022
1	Irbesartan FDA LinkGeneric 10/2021
1	Losartan (Cozaar)FDA LinkGeneric 10/2021
1	Angiotensin II Type 1 Receptor BlockersIBA 10/2021
1	Angiotensin IIIBA 10/2021
1	Apolipoprotein L1IBA 01/2021
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2021

Therapy/Procedure

32	Therapeutics 01/2022 - 09/2003
5	Glycemic Control 10/2020 - 09/2008
4	Drug Therapy (Chemotherapy) 01/2022 - 10/2014
3	Renal Replacement Therapy (Therapies, Renal Replacement) 12/2017 - 01/2014
3	High-Protein Diet 07/2013 - 07/2003
2	Renal Dialysis (Hemodialysis) 12/2022 - 10/2020
2	Surgical Amputation (Amputations) 01/2022 - 01/2005
2	Precision Medicine 01/2021 - 01/2021
2	Stents 11/2016 - 12/2015
2	Mediterranean Diet 09/2011 - 07/2006
1	Peritoneal Dialysis 12/2022
1	Caloric Restriction 01/2022
1	Nutrition Therapy (Medical Nutrition Therapy) 01/2022